Sponsor pipeline

Imugene Limited clinical trial pipeline

Get alerts when Imugene Limited's trials change

2 active trials 2 recruiting 4 disease areas 3 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-16

What changed in the last 30 days

2026-09-09
Interventions modified
Trial sites reduced: 23 → 15 locations
Trial arms changed: 6 → 7
NCT03666000 Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in… · Phase 1

Active trials by phase

Phase 1
1
Not charted: 1 active trial with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials

NCT IDTitleConditionStatusUpdated
Phase 1
NCT03666000 Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in… Non-Hodgkin Lymphoma Recruiting 2026-09-08
Not specified
NCT05822427 Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen… Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study Recruiting 2025-05-14

Disease areas by active trials

Acute Lymphoblastic Leukemia (ALL) (1) · Chronic Lymphocytic Leukemia (CLL) (1) · Leukemia (1) · Non-Hodgkin Lymphoma (1)

Get alerts when Imugene Limited's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free